Oxford BioDynamics PLC Appointment of Paul Stockdale as CFO (6674J)
June 30 2017 - 2:01AM
UK Regulatory
TIDMOBD
RNS Number : 6674J
Oxford BioDynamics PLC
30 June 2017
30 June 2017
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Appointment of Paul Stockdale as Chief Financial Officer
Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology
company focused on the discovery and development of epigenetic
biomarkers based on regulatory genome architecture, for use within
the pharmaceutical and biotechnology industry, today announces the
appointment of Paul Stockdale as Chief Financial Officer (CFO).
Paul is expected to join the Company by 15 September 2017 and will
be appointed to the Board of Directors in due course.
Paul succeeds Katie Long who is returning to her role within
Tessera Investment Management Limited ("Tessera"), having
established and led OBD's finance function over the previous nine
months and during the Company's IPO. Katie will step down from the
Board on 30 June 2017 and will support OBD on an interim basis in
the transitional period.
Paul joins the Company from e-Therapeutics plc (AIM:ETX), where
he has held the position of Financial Controller since January
2012. During this time he has worked closely with the CFO and has
been responsible for internal and external financial reporting, and
developing and maintaining financial and operational systems. Paul
is a Chartered Accountant and was a Senior Manager at Deloitte,
where he worked from 1996 until 2004. Following this, he worked in
finance and operations management in the charitable and automotive
sectors. He read Natural Sciences at St John's College, University
of Cambridge.
Christian Hoyer Millar, Chief Executive Officer of Oxford
BioDynamics, said:
"We are delighted to welcome Paul Stockdale to the Company.
Paul's extensive financial management experience, including his
recent experience in another public company focused on drug
discovery, will be important as OBD strides towards becoming the
industry standard for epigenetic biomarker discovery.
The Board would like to take this opportunity to thank Katie for
her invaluable contribution during this pivotal time for OBD. We
wish her well on her return to Tessera."
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies. Paul Leslie
Stockdale, aged 42 years, has been a director of the following
companies during the five years preceding the date of this
announcement:
Current directorships Past Directorships
None PL & JE Services Limited
The Company confirms that there is no further information to be
disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the
AIM Rules for Companies.
For further details contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar,
CEO
Katie Long, CFO
Stifel Nicolaus Europe
Limited +44 (0)20 7710 7600
Nominated Advisor and
Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Shore Capital +44 (0)20 7408 4090
Joint Broker
Bidhi Bhoma
Edward Mansfield
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
revenue--generating biotechnology company focused on the discovery
and development of epigenetic biomarkers for use within the
pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALFFIIRLIAFID
(END) Dow Jones Newswires
June 30, 2017 02:01 ET (06:01 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2023 to Apr 2024